Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06691893 · ClinicalTrials.gov registry record · Phase 3

Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients

A Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI), sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 3
Development phase
60
Enrollment target
1
Study location

NCT06691893: Recruiting Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI), sponsored by Massachusetts General Hospital.

NCT06691893 is a Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI) that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 60 participants, below the 619-participant average among 17 other Pancreatitis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06691893, a Phase 3 study of Pancreatitis and Exocrine Pancreatic Insufficiency (EPI), is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzyme replacement therapy (PERT) is commonly used to manage EPI symptoms, it can be challenging for people who rely on feeding tubes. RELiZORB, could help these patients by simplifying the delivery of the enzymes they need. However, RELiZORB has only been studied in people with EPI caused by cystic fibrosis, so its effectiveness in pancreatitis patients remains unknown. This study aims to determine whether RELiZORB is effective for individuals requiring feeding tube support after pancreatitis.

Primary Outcome

The PEI-Q is an 18-item Patient-Reported Outcome (PRO) questionnaire designed to help individuals with pancreatic exocrine insufficiency (PEI) assess their symptoms and the impact on their health-related quality of life. Created and validated by Adelphi Values UK in collaboration with Abbott, the PEI-Q is available for use in clinical studies without the need to purchase a license. The scoring system ranges from 0 to 4, with higher scores indicating more severe symptoms. A score between 0.6 and

Conditions Studied

Pancreatitis Exocrine Pancreatic Insufficiency (EPI)

Interventions

  • DEVICE RELiZORB

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-03-28
Est. Completion 2027-07-15
Phase Phase 3
Massachusetts General Hospital

2,032 total trials

What NCT06691893 shows while recruiting

NCT06691893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 619-participant average among 17 other Pancreatitis trials with a reported enrollment target (90% lower).

The record links to 2 conditions, with Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which RELiZORB is the first listed.

NCT06691893 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06691893 about?

NCT06691893 is a clinical study titled "Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients". This research aims to improve the management of exocrine pancreatic insufficiency (EPI), a condition that can develop after pancreatitis, a painful inflammation of the pancreas. EPI occurs when the pancreas does not produce enough enzymes to help the body properly digest food. While pancreatic enzym...

What is the current status of trial NCT06691893?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2025-03-28. Estimated completion is 2027-07-15.

What conditions does trial NCT06691893 study?

This clinical trial studies the following conditions: Pancreatitis, Exocrine Pancreatic Insufficiency (EPI).

What interventions are being tested in trial NCT06691893?

The interventions under investigation include: RELiZORB (DEVICE).

Who is sponsoring clinical trial NCT06691893?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06691893 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06691893's enrollment target sits among peer trials

60 13th of 17 higher than 4 of 17 other Pancreatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06691893

Source: ClinicalTrials.gov NCT06691893, the US trial registry maintained by the National Library of Medicine. NCT06691893 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.